Skip to content

A prospective multicenter, randomized, controlled clinical study on the efficacy of new regimens for eradication of Helicobacter pylori

A prospective multicenter, randomized, controlled clinical study on the efficacy of new regimens for eradication of Helicobacter pylori

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040855
Enrollment
Unknown
Registered
2020-12-12
Start date
2020-12-15
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infecion

Interventions

A:minocycline (100mg twice a day) +clarithromycin(500mg,twice a day)+ bismuth(220mg,twice a day)+esomeprazole(20mg, twice a day) for two weeks
B:minocycline (100mg twice a day)+levofloxacin(500mg,twice a day)+ bismuth(220mg,twice a day)+esomeprazole(20mg, twice a day) for two weeks
C:clarithromycin (500mg twice a day) +axoxicillin(500mg,twice a day)+ bismuth(220mg,twice a day)+esomeprazole(20mg, twice a day) for two weeks

Sponsors

Fujian Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients, aged between 18-70 years. 2. Patients who did not take antibiotics, bismuth and traditional Chinese medicine 4 weeks before treatment, and patients who took PPI, H2 receptor antagonists and other drugs that affect HP activity 2 weeks before treatment; 3. Patients who were diagnosed as HP positive by C13 or C14 urea breath test, rapid urease test and histopathology, and who had not received HP eradication treatment before; 4. Informed and agreed to participate in the study, patients with complete medical records and follow-up records.

Exclusion criteria

Exclusion criteria: 1. With severe heart, lung, and kidney dysfunction and low immunity; 2. Patients with drug allergy contraindications; 3. Persons with mental illness or communication difficulties; 4. Pregnancy, lactation; 5. Patients with organic diseases such as gastrointestinal tumor and gastrointestinal hemorrhage.

Design outcomes

Primary

MeasureTime frame
eradication rate;

Secondary

MeasureTime frame
adverse reaction;antibiotic resistance of Helicobacter pylori;

Countries

China

Contacts

Public ContactZhihui Lin

Fujian Provincial Hospital

303622465@qq.com+86 13799371368

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026